Shares of Cardiff Oncology Inc. (CRDF) are up over 25% at $2.21 in premarket trading today, following a business update provided by the clinical-stage biotechnology company.
The company's lead drug candidate is Onvansertib, a PLK1 inhibitor, being evaluated in combination with standard-of-care (SoC) therapeutics in a range of cancers.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.